Back to News & Events

Long Island Bioscience Hub Announces Next Funded Projects

Accelerating the development of biomedical technologies

The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), has announced the recipients of the second round of funded projects under the Hub’s technology development and commercialization initiative. Funding for ten projects totaling $600,000 was awarded to applicants from the Hub’s partner institutions. Partner institutions include Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute at Northwell Health Systems.

The technology development awards made available by the LIBH are specifically aimed at growing a pipeline of commercially promising biomedical technologies that can be out-licensed for further development or serve as the foundation for new company formations in the region. There are two tiers of funding, each with the goal of accelerating technology development to reach a critical development inflection point. Feasibility awards ($50,000) are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications. Proof-of-Concept Awards ($100,000) provide targeted, milestone driven support for further development, testing, and analysis of existing intellectual property.

A wide range of disciplines are represented in the project awards this cycle including biomedical engineering, chemistry, biochemistry, psychiatry, molecular genetics and microbiology, and pathology and dermatology.  Eight Feasibility awards and two Proof of Concepts awards have been funded this cycle. The recipients of this round of awards are:

Feasibility Awards

Therapeutic for Clostridium difficile antibiotic-associated diarrheal disease – Dr. James Bliska

Device for rapid, simple and highly parallel single-cell processing – Dr. Eric Brouzes

Developing a small molecule drug to treat systemic C. albicans infections – Dr. Nick Carpino

Next generation hedgehog inhibitor for invasive basal cell carcinoma – Dr. Jiang Chen

A Novel Strategy for Recombinant AAV Vector Production for Gene Therapy – Dr. Patrick Hearing

A tandem-integration-based multi-barcode method for high-throughput combinatorial screening – Dr. Sasha Levy

Novel CAIX Targeted Combination Inhibitor/PET tracer to treat patients with solid tumors – Dr. Peter Smith-Jones

Substrate-Assisted Tethered Inhibitors of LigA to Treat MDR Gonorrhea – Dr. Peter Tonge

Proof of Concept Awards

fMRI Dynamic Phantom for Improved Detection of Resting-State Brain Networks – Dr. Lilianne Mujica-Parodi

Development of SMASH technology as a next-gen sequencing diagnostic for congenital heart disease – Dr. Michael Ronemus

​“The announcement of this second cycle of awards from the Long Island Bioscience Hub under the NIH-REACH program is exemplary of the increasing commercially relevant research taking place in the region” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “Coupled with the recent expansion of the Hub to include the Feinstein Institute and the announcement of our third “request for proposals,” the LIBH is steadily working toward its goal of accelerating the translation of these technologies from the bench to the bed side.”

The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.

Download a PDF of the press release here.

 

 

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 5065
                    [post_author] => 4
                    [post_date] => 2026-09-01 14:03:32
                    [post_date_gmt] => 2026-09-01 18:03:32
                    [post_content] => 

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.

BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.

Application deadline: October 29, 2026, 5:00pm ET

For info sessions, eligibility and deadlines visit our REACH Website and FAQ.

The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.

Questions? Reach out to our program contacts or sign up for office hours:

Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here

Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here

[post_title] => BioREACH: Translational Research Funding Opportunity [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bioreach-translational-research-funding-opportunity [to_ping] => [pinged] => [post_modified] => 2026-09-04 11:55:36 [post_modified_gmt] => 2026-09-04 15:55:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5065 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2621 [post_author] => 3 [post_date] => 2017-03-20 13:58:38 [post_date_gmt] => 2017-03-20 13:58:38 [post_content] => CEWIT, the Center for Biotechnology and Henry Schein, Inc., have joined forces to host an expert symposium presenting cutting-edge advances in biomedical and clinical-related technologies, digital health, and smart medical devices, focusing on the technology as well as the joint industry, academic, and R&D partnerships that are integral to major innovations in the healthtech domain — at Stony Brook University. Tuesday, March 28, 2017, 9:30am-3:30pm The Center of Excellence in Wireless and Information Technology (CEWIT) at Stony Brook University 1500 Stony Brook Road, Stony Brook, NY 11794-6040 Event is free but registration is requires. View full agenda and register here: www.cewit.org/events/healthtech.html [post_title] => CEWIT Medical Technologies and Healthcare Innovations Symposium [post_excerpt] => Featuring cutting-edge advances in biomedical and clinical-related technologies, digital health, and smart medical devices, focusing on the technology as well as the joint industry, academic, and R&D partnerships that are integral to major innovations in the healthtech domain — at Stony Brook University. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => cewit-medical-technologies-and-healthcare-innovations-symposium [to_ping] => [pinged] => [post_modified] => 2017-03-20 13:59:29 [post_modified_gmt] => 2017-03-20 13:59:29 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2621 [menu_order] => 151 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3181 [post_author] => 3 [post_date] => 2019-02-28 16:35:02 [post_date_gmt] => 2019-02-28 16:35:02 [post_content] => Center for Biotechnology Director Dr. Clinton Rubin has co-authored a recent article published in Nature Reviews Endocrinology "“Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity”.  Abstract below, full article here. Abstract:  Osteoporosis, a condition of skeletal decline that undermines quality of life, is treated with pharmacological interventions that are associated with poor adherence and adverse effects. Complicating efforts to improve clinical outcomes, the incidence of obesity is increasing, predisposing the population to a range of musculoskeletal complications and metabolic disorders. Pharmacological management of obesity has yet to deliver notable reductions in weight and debilitating complications are rarely avoided. By contrast, exercise shows promise as a non-invasive and non-pharmacological method of regulating both osteoporosis and obesity. The principal components of exercise — mechanical signals — promote bone and muscle anabolism while limiting formation and expansion of fat mass. Mechanical regulation of bone and marrow fat might be achieved by regulating functions of differentiated cells in the skeletal tissue while biasing lineage selection of their common progenitors — mesenchymal stem cells. An inverse relationship between adipocyte versus osteoblast fate selection from stem cells is implicated in clinical conditions such as childhood obesity and increased marrow adiposity in type 2 diabetes mellitus, as well as contributing to skeletal frailty. Understanding how exercise-induced mechanical signals can be used to improve bone quality while decreasing fat mass and metabolic dysfunction should lead to new strategies to treat chronic diseases such as osteoporosis and obesity. [post_title] => “Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity” [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => combating-osteoporosis-and-obesity-with-exercise-leveraging-cell-mechanosensitivity [to_ping] => [pinged] => [post_modified] => 2019-04-09 14:40:26 [post_modified_gmt] => 2019-04-09 14:40:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3181 [menu_order] => 100 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4519 [post_author] => 4 [post_date] => 2024-11-08 11:33:54 [post_date_gmt] => 2024-11-08 16:33:54 [post_content] =>

The CFB was proud to support our clients, Ergami Endoscopy and FASS, who were each announced as winners of $50,000 after pitching their business plans to a panel of judges assembled by FuzeHub at the recent New York State Innovation Summit.

FuzeHub is a not-for-profit organization that supports small and medium-sized manufacturing companies in New York State, hosts this annual as part of the ESD-supported FuzeHub Jeff Lawrence Innovation Fund.

Ergami Endoscopy, based in New York City, is developing a low-cost robotic colonoscope insertion solution to improve procedure productivity; reduce patient pain and need for sedation; and reduce endoscopy-related injuries in endoscopists and nurses.

FASS is a unique syringe system that uses a rotating mechanism to switch between two needles in a single device, eliminating the need for manual switching of needles. Developed by an ER nurse after witnessing the dangers of needlestick injuries firsthand, FASS is designed to improve safety and efficiency in high-pressure environments like the ER and psychiatric units, where patients can be agitated.

Read more about the competition here.

[post_title] => CFB Clients Tapped as FuzeHub Commercialization Competition Winners [post_excerpt] => The CFB was proud to support two clients in efforts in the FuzeHub Commercialization Competition. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => cfb-clients-tapped-as-fuzehub-commercialization-competition-winners [to_ping] => [pinged] => https://fuzehub.com/manufacturing-blog/fuzehub-announces-2024-new-york-state-innovation-summit-commercialization-competition-winners/ [post_modified] => 2025-05-01 12:38:12 [post_modified_gmt] => 2025-05-01 16:38:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4519 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 5065 [post_author] => 4 [post_date] => 2026-09-01 14:03:32 [post_date_gmt] => 2026-09-01 18:03:32 [post_content] =>

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.

BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.

Application deadline: October 29, 2026, 5:00pm ET

For info sessions, eligibility and deadlines visit our REACH Website and FAQ.

The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.

Questions? Reach out to our program contacts or sign up for office hours:

Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here

Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here

[post_title] => BioREACH: Translational Research Funding Opportunity [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bioreach-translational-research-funding-opportunity [to_ping] => [pinged] => [post_modified] => 2026-09-04 11:55:36 [post_modified_gmt] => 2026-09-04 15:55:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5065 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 288 [max_num_pages] => 96 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

BioREACH: Translational Research Funding Opportunity

More Information

CEWIT Medical Technologies and Healthcare Innovations Symposium

More Information

“Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity”

More Information

CFB Clients Tapped as FuzeHub Commercialization Competition Winners

More Information